Novel Vaccine Technologies in Veterinary Medicine: A Herald to Human Medicine Vaccines.

Autor:	Aida V; Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States.; Emory-University of Georgia (UGA) Center of Excellence for Influenza Research and Surveillance (CEIRS), Auburn, AL, United States., Pliasas VC; Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States.; Emory-University of Georgia (UGA) Center of Excellence for Influenza Research and Surveillance (CEIRS), Auburn, AL, United States., Neasham PJ; Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States.; Emory-University of Georgia (UGA) Center of Excellence for Influenza Research and Surveillance (CEIRS), Auburn, AL, United States., North JF; Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States.; Emory-University of Georgia (UGA) Center of Excellence for Influenza Research and Surveillance (CEIRS), Auburn, AL, United States., McWhorter KL; Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States.; Department of Chemistry, Emory University, Atlanta, GA, United States., Glover SR; Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States.; Emory-University of Georgia (UGA) Center of Excellence for Influenza Research and Surveillance (CEIRS), Auburn, AL, United States., Kyriakis CS; Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, United States.; Emory-University of Georgia (UGA) Center of Excellence for Influenza Research and Surveillance (CEIRS), Auburn, AL, United States.; Center for Vaccines and Immunology, University of Georgia, Athens, GA, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in veterinary science [Front Vet Sci] 2021 Apr 15; Vol. 8, pp. 654289. Date of Electronic Publication: 2021 Apr 15 (Print Publication: 2021).
DOI:	10.3389/fvets.2021.654289
Abstrakt:	The success of inactivated and live-attenuated vaccines has enhanced livestock productivity, promoted food security, and attenuated the morbidity and mortality of several human, animal, and zoonotic diseases. However, these traditional vaccine technologies are not without fault. The efficacy of inactivated vaccines can be suboptimal with particular pathogens and safety concerns arise with live-attenuated vaccines. Additionally, the rate of emerging infectious diseases continues to increase and with that the need to quickly deploy new vaccines. Unfortunately, first generation vaccines are not conducive to such urgencies. Within the last three decades, veterinary medicine has spearheaded the advancement in novel vaccine development to circumvent several of the flaws associated with classical vaccines. These third generation vaccines, including DNA, RNA and recombinant viral-vector vaccines, induce both humoral and cellular immune response, are economically manufactured, safe to use, and can be utilized to differentiate infected from vaccinated animals. The present article offers a review of commercially available novel vaccine technologies currently utilized in companion animal, food animal, and wildlife disease control. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Aida, Pliasas, Neasham, North, McWhorter, Glover and Kyriakis.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu